Report #2827898

Received Feb 24, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

patients were late for their second dose after COVID years ago/ interval longer; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in an unspecified number of patients who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patients were late for their second dose after COVID years ago/ interval longer). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 18-FEB-2025 Pharmacist stated various patients were late for their second dose after Covid years ago. Pharmacist stated no further information was available regarding number of patients (maybe 2 a year but unknown) and no further details were available. The patients received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule.